anurajms/meta_analysis huggingface dataset:
MESH terms:
Laparoscopic‐endoscopic rendezvous versus preoperative endoscopic sphincterotomy in people undergoing laparoscopic cholecystectomy for stones in the gallbladder and bile duct
1. Cholecystectomy, Laparoscopic [adverse effects, *methods]; 2. Choledocholithiasis [complications, *surgery]; 3. Gallstones [complications, *surgery]; 4. Length of Stay; 5. Operative Time; 6. Randomized Controlled Trials as Topic; 7. Sphincterotomy, Endoscopic [adverse effects, *methods];
MESH terms:
Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Administration, Oral; 2. Aggression [*drug effects, psychology]; 3. Antipsychotic Agents [adverse effects, *therapeutic use]; 4. Carbamazepine [analogs & derivatives, therapeutic use]; 5. Oxcarbazepine; 6. Psychomotor Agitation [*drug therapy]; 7. Psychotic Disorders [*complications, drug therapy, psychology]; 8. Quetiapine Fumarate [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Risperidone [adverse effects, *therapeutic use]; 11. Tranquilizing Agents [therapeutic use]; 12. Valproic Acid [therapeutic use];
MESH terms:
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
1. Administration, Oral; 2. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 3. Disease Progression; 4. Drug Administration Schedule; 5. Glucocorticoids [administration & dosage, adverse effects]; 6. Methylprednisolone [administration & dosage, adverse effects]; 7. Prednisolone [administration & dosage, adverse effects]; 8. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Treatment Failure;
MESH terms:
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
1. Antipsychotic Agents [*administration & dosage, *adverse effects]; 2. Dose‐Response Relationship, Drug; 3. Drug Administration Schedule; 4. Drug Substitution; 5. Dyskinesia, Drug‐Induced [*drug therapy, prevention & control]; 6. Mental Disorders [drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Schizophrenia [drug therapy]; 9. Withholding Treatment;
MESH terms:
Fitness training for cardiorespiratory conditioning after traumatic brain injury
1. *Cardiovascular Deconditioning; 2. *Exercise Therapy; 3. *Physical Fitness; 4. Brain Injuries [complications, *rehabilitation]; 5. Physical Conditioning, Human; 6. Randomized Controlled Trials as Topic;
MESH terms:
Peritoneal dialysis for acute kidney injury
1. *Peritoneal Dialysis [adverse effects, mortality, statistics & numerical data]; 2. Acidosis [therapy]; 3. Acute Kidney Injury [mortality, *therapy]; 4. Cause of Death; 5. Randomized Controlled Trials as Topic; 6. Recovery of Function; 7. Renal Dialysis [methods];
MESH terms:
Personalised asthma action plans for adults with asthma
1. *Patient Education as Topic; 2. Asthma [complications, *drug therapy, mortality]; 3. Disease Progression; 4. Emergency Medical Services [statistics & numerical data]; 5. Hospitalization [statistics & numerical data]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Self Care [adverse effects, *methods, mortality];
MESH terms:
Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
1. Bronchi [surgery]; 2. Bronchoscopy [*methods]; 3. Pneumonectomy [adverse effects, *methods]; 4. Pulmonary Disease, Chronic Obstructive [*surgery]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Fibrin glue for pilonidal sinus disease
1. Combined Modality Therapy [methods]; 2. Fibrin Tissue Adhesive [adverse effects, *therapeutic use]; 3. Pilonidal Sinus [etiology, surgery, *therapy]; 4. Randomized Controlled Trials as Topic; 5. Surgical Flaps; 6. Surgical Procedures, Operative [adverse effects, methods]; 7. Time Factors; 8. Tissue Adhesives [adverse effects, *therapeutic use]; 9. Wound Healing;
MESH terms:
Intensive case management for severe mental illness
1. *Case Management; 2. Community Mental Health Services [*methods]; 3. Employment [statistics & numerical data]; 4. Hospitalization [statistics & numerical data]; 5. Mental Disorders [*therapy]; 6. Outcome and Process Assessment, Health Care [*methods]; 7. Randomized Controlled Trials as Topic; 8. Regression Analysis; 9. Suicide [statistics & numerical data];
MESH terms:
Protease‐modulating matrix treatments for healing venous leg ulcers
1. *Bandages; 2. *Wound Healing; 3. Alginates [therapeutic use]; 4. Bandages, Hydrocolloid; 5. Cellulose [therapeutic use]; 6. Collagen [therapeutic use]; 7. Gels [therapeutic use]; 8. Peptide Hydrolases [*metabolism]; 9. Randomized Controlled Trials as Topic; 10. Silver [*therapeutic use]; 11. Time Factors; 12. Varicose Ulcer [*enzymology, *therapy];
MESH terms:
Non‐steroidal anti‐inflammatory drugs for sciatica
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Cyclooxygenase Inhibitors [therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Sciatica [*drug therapy];
MESH terms:
Lung volume reduction surgery for diffuse emphysema
1. Laser Therapy; 2. Lung [*surgery]; 3. Pneumonectomy [*methods, mortality]; 4. Pulmonary Emphysema [mortality, rehabilitation, *surgery]; 5. Randomized Controlled Trials as Topic; 6. Surgical Stapling; 7. Sutures;
MESH terms:
Fast‐track cardiac care for adult cardiac surgical patients
1. *Coronary Artery Bypass; 2. *Heart Valve Prosthesis Implantation; 3. *Intubation, Intratracheal; 4. Aortic Aneurysm [*surgery]; 5. Aortic Valve [surgery]; 6. Controlled Clinical Trials as Topic; 7. Early Ambulation; 8. Length of Stay; 9. Mitral Valve [surgery]; 10. Randomized Controlled Trials as Topic; 11. Risk; 12. Time Factors;
MESH terms:
Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults
1. Acute Disease; 2. Acute Lung Injury [*drug therapy, mortality]; 3. Administration, Inhalation; 4. Hypoxia [*drug therapy, mortality]; 5. Length of Stay; 6. Nitric Oxide [*administration & dosage, adverse effects]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Distress Syndrome [drug therapy, mortality]; 9. Respiratory Insufficiency [*drug therapy, mortality]; 10. Vasodilator Agents [adverse effects, *therapeutic use];
MESH terms:
Manual therapy and exercise for rotator cuff disease
1. *Musculoskeletal Manipulations; 2. *Rotator Cuff; 3. Exercise Therapy [*methods]; 4. Muscular Diseases [*therapy]; 5. Randomized Controlled Trials as Topic; 6. Shoulder Pain [etiology, *therapy];
MESH terms:
Back schools for acute and subacute non‐specific low‐back pain
1. *Exercise Therapy; 2. *Patient Education as Topic; 3. *Program Evaluation; 4. Acute Pain [*therapy]; 5. Diathermy; 6. Low Back Pain [*therapy]; 7. Musculoskeletal Manipulations; 8. Randomized Controlled Trials as Topic;
MESH terms:
Risperidone (depot) for schizophrenia
1. Administration, Oral; 2. Antipsychotic Agents [*therapeutic use]; 3. Aripiprazole [therapeutic use]; 4. Benzodiazepines [therapeutic use]; 5. Delayed‐Action Preparations [therapeutic use]; 6. Olanzapine; 7. Patient Dropouts [statistics & numerical data]; 8. Quetiapine Fumarate [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Risperidone [*therapeutic use]; 11. Schizophrenia [*drug therapy];
MESH terms:
Surgical versus conservative interventions for treating anterior cruciate ligament injuries
1. *Anterior Cruciate Ligament Injuries; 2. Anterior Cruciate Ligament Reconstruction [*methods]; 3. Joint Instability [etiology, rehabilitation, *therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Care delivery and self management strategies for adults with epilepsy
1. Delivery of Health Care [*methods]; 2. Epilepsy [nursing, *therapy]; 3. Neurology; 4. Outcome and Process Assessment, Health Care; 5. Patient Education as Topic [methods]; 6. Randomized Controlled Trials as Topic; 7. Self Care [*methods];
MESH terms:
Motor control exercise for chronic non‐specific low‐back pain
1. *Muscle Contraction; 2. Chronic Pain [*therapy]; 3. Exercise Therapy [*methods]; 4. Low Back Pain [*therapy]; 5. Pain Measurement; 6. Paraspinal Muscles [*physiology]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Multi‐disciplinary rehabilitation for acquired brain injury in adults of working age
1. Age Factors; 2. Brain Injuries [etiology, *rehabilitation]; 3. Cognitive Behavioral Therapy; 4. Counseling; 5. Critical Care [*methods, standards]; 6. Patient Care Team; 7. Randomized Controlled Trials as Topic; 8. Rehabilitation, Vocational; 9. Stroke [complications];
MESH terms:
Crisis intervention for people with severe mental illnesses
1. Caregivers [psychology]; 2. Crisis Intervention [*methods]; 3. Mental Disorders [psychology, *therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Rehabilitation for distal radial fractures in adults
1. Fractures, Bone [rehabilitation]; 2. Physical Therapy Modalities; 3. Radius Fractures [*rehabilitation]; 4. Randomized Controlled Trials as Topic; 5. Wrist Injuries [*rehabilitation];
MESH terms:
Early versus delayed dressing removal after primary closure of clean and clean‐contaminated surgical wounds
1. *Bandages [adverse effects, statistics & numerical data]; 2. *Surgical Wound Infection [epidemiology]; 3. *Wound Closure Techniques; 4. *Wound Healing; 5. Early Medical Intervention; 6. Hospital Costs; 7. Length of Stay; 8. Randomized Controlled Trials as Topic; 9. Surgical Wound Dehiscence [epidemiology]; 10. Time Factors;
MESH terms:
Social skills programmes for schizophrenia
1. *Social Skills; 2. Assertiveness; 3. Communication; 4. Cultural Characteristics; 5. Patient Readmission [statistics & numerical data]; 6. Program Evaluation; 7. Psychotic Disorders [*rehabilitation]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Schizophrenia [*rehabilitation]; 12. Schizophrenic Psychology; 13. Stress, Psychological [*rehabilitation];
MESH terms:
Cognitive‐behavioural treatment for subacute and chronic neck pain
1. Acute Pain [psychology, *therapy]; 2. Chronic Pain [psychology, *therapy]; 3. Cognitive Behavioral Therapy [*methods]; 4. Neck Pain [psychology, *therapy]; 5. Pain Management [*methods]; 6. Randomized Controlled Trials as Topic; 7. Selection Bias;
MESH terms:
Use of plastic adhesive drapes during surgery for preventing surgical site infection
1. *Adhesives; 2. *Plastics; 3. Iodine [therapeutic use]; 4. Length of Stay; 5. Randomized Controlled Trials as Topic; 6. Surgical Drapes [*adverse effects]; 7. Surgical Wound Infection [*prevention & control];
MESH terms:
Supportive therapy for schizophrenia
1. Antipsychotic Agents [therapeutic use]; 2. Family Therapy; 3. Intention to Treat Analysis; 4. Mental Health Services; 5. Patient Satisfaction; 6. Psychotherapy [methods]; 7. Randomized Controlled Trials as Topic; 8. Schizophrenia [*therapy]; 9. Schizophrenic Psychology; 10. Social Support;
MESH terms:
Hydrogel dressings for treating pressure ulcers
1. *Bandages, Hydrocolloid; 2. Collagenases [therapeutic use]; 3. Dextrans [therapeutic use]; 4. Hydrogels [*therapeutic use]; 5. Ointments; 6. Pressure Ulcer [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Protocolized versus non‐protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients
1. *Critical Illness; 2. Clinical Protocols [standards]; 3. Intensive Care Units [statistics & numerical data]; 4. Length of Stay; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [adverse effects, *statistics & numerical data]; 7. Time Factors; 8. Ventilator Weaning [adverse effects, *methods];
MESH terms:
Minimally invasive discectomy versus microdiscectomy/open discectomy for symptomatic lumbar disc herniation
1. Artificial Limbs; 2. Diskectomy [*methods]; 3. Intervertebral Disc Displacement [*surgery]; 4. Length of Stay; 5. Low Back Pain [surgery]; 6. Lumbosacral Region; 7. Microsurgery [methods]; 8. Outcome Assessment, Health Care; 9. Pain Measurement; 10. Randomized Controlled Trials as Topic; 11. Sciatica [surgery];
MESH terms:
Platelet‐rich therapies for musculoskeletal soft tissue injuries
1. *Platelet‐Rich Plasma; 2. Achilles Tendon [injuries]; 3. Anterior Cruciate Ligament Reconstruction; 4. Blood Transfusion, Autologous; 5. Platelet Transfusion [*methods]; 6. Randomized Controlled Trials as Topic; 7. Rotator Cuff Injuries; 8. Shoulder Impingement Syndrome [therapy]; 9. Soft Tissue Injuries [*therapy]; 10. Tendinopathy [therapy]; 11. Tennis Elbow [therapy];
MESH terms:
Bronchial thermoplasty for moderate or severe persistent asthma in adults
1. Asthma [*therapy]; 2. Bronchi [*surgery]; 3. Disease Progression; 4. Emergency Service, Hospital [statistics & numerical data]; 5. Hospitalization [statistics & numerical data]; 6. Hypertrophy [therapy]; 7. Muscle, Smooth [pathology]; 8. Pulsed Radiofrequency Treatment [adverse effects, *methods]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Time Factors;
MESH terms:
Trifluoperazine versus placebo for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Dyskinesia, Drug‐Induced [etiology]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia [*drug therapy]; 5. Trifluoperazine [adverse effects, *therapeutic use];
MESH terms:
Enhanced care by generalists for functional somatic symptoms and disorders in primary care
1. General Practice [*methods]; 2. Psychophysiologic Disorders [*therapy]; 3. Randomized Controlled Trials as Topic;
MESH terms:
User‐held personalised information for routine care of people with severe mental illness
1. *Health Records, Personal; 2. Hospitalization [statistics & numerical data]; 3. Patient Access to Records; 4. Psychotic Disorders [*therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Traction for low‐back pain with or without sciatica
1. *Traction [adverse effects]; 2. Acute Pain [therapy]; 3. Chronic Pain [therapy]; 4. Low Back Pain [complications, *therapy]; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic; 7. Sciatica [complications, *therapy];
MESH terms:
Dressings for superficial and partial thickness burns
1. *Wound Healing; 2. Bandages [classification, *standards]; 3. Bandages, Hydrocolloid; 4. Burns [physiopathology, *therapy]; 5. Randomized Controlled Trials as Topic; 6. Silicon Compounds [therapeutic use]; 7. Silver Sulfadiazine [therapeutic use]; 8. Skin, Artificial;
MESH terms:
Inhaled corticosteroids for subacute and chronic cough in adults
1. Acute Disease; 2. Administration, Inhalation; 3. Adrenal Cortex Hormones [*administration & dosage]; 4. Antitussive Agents [*administration & dosage]; 5. Chronic Disease; 6. Cough [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Treatment Outcome;
MESH terms:
Nurse versus physician‐led care for the management of asthma
1. *Disease Management; 2. *Practice Patterns, Nurses'; 3. *Practice Patterns, Physicians'; 4. Asthma [*therapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults
1. Constriction, Pathologic; 2. *Kidney Calculi [surgery]; 3. *Lithotripsy; 4. *Nephrolithotomy, Percutaneous [adverse effects]; 5. Quality of Life; 6. *Ureteral Obstruction;
MESH terms:
Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones
1. *Kidney Calculi [surgery]; 2. Length of Stay; 3. *Nephrolithotomy, Percutaneous [adverse effects]; 4. Pain, Postoperative [epidemiology]; 5. *Ureter;
MESH terms:
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
1. Angiotensin Receptor Antagonists [adverse effects]; 2. Angiotensin-Converting Enzyme Inhibitors [adverse effects]; 3. *Diabetes Mellitus [drug therapy]; 4. Losartan [therapeutic use]; 5. Proteinuria; 6. *Renal Insufficiency, Chronic [complications, drug therapy];
MESH terms:
Interventions for improving health literacy in people with chronic kidney disease
1. *Health Literacy; 2. *Renal Insufficiency, Chronic [therapy];
MESH terms:
Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis
1. *Catheter-Related Infections [etiology, prevention & control]; 2. *Central Venous Catheters [adverse effects]; 3. Heparin [therapeutic use]; 4. Renal Dialysis [adverse effects]; 5. *Sepsis [drug therapy];
MESH terms:
Interventions for minimal change disease in adults with nephrotic syndrome
1. *Acute Kidney Injury [chemically induced]; 2. Calcineurin Inhibitors [adverse effects]; 3. Immunosuppressive Agents [adverse effects]; 4. Levamisole [therapeutic use]; 5. Methylprednisolone [therapeutic use]; 6. Mycophenolic Acid [therapeutic use]; 7. *Nephrosis, Lipoid [chemically induced, complications, drug therapy]; 8. *Nephrotic Syndrome [chemically induced, complications, drug therapy]; 9. Recurrence; 10. Steroids [therapeutic use];
MESH terms:
Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. *Acute Kidney Injury [prevention & control]; 2. Blood Coagulation; 3. *Continuous Renal Replacement Therapy; 4. Kidney; 5. Randomized Controlled Trials as Topic;
MESH terms:
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
1. Bias; 2. Cardiovascular Diseases [chemically induced]; 3. Cause of Death; 4. Cerebrovascular Disorders [chemically induced]; 5. Eplerenone [adverse effects, therapeutic use]; 6. Gynecomastia [chemically induced]; 7. Hyperkalemia [chemically induced]; 8. Mineralocorticoid Receptor Antagonists [adverse effects, *therapeutic use]; 9. Placebos [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. *Renal Dialysis; 12. Renal Insufficiency, Chronic [mortality, *therapy]; 13. Spironolactone [adverse effects, therapeutic use];
MESH terms:
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. Acute Kidney Injury [mortality, *therapy]; 2. Anticoagulants [*administration & dosage, adverse effects]; 3. Bias; 4. Blood Coagulation [*drug effects]; 5. *Catheter Obstruction [etiology]; 6. Citric Acid [administration & dosage, adverse effects]; 7. Continuous Renal Replacement Therapy [adverse effects, *instrumentation, mortality]; 8. Filtration [instrumentation]; 9. Hemorrhage [chemically induced, prevention & control]; 10. Heparin [administration & dosage, adverse effects]; 11. Heparin, Low-Molecular-Weight [administration & dosage, adverse effects]; 12. Kidney [physiology]; 13. Patient Dropouts; 14. Randomized Controlled Trials as Topic; 15. Recovery of Function [drug effects]; 16. Thrombocytopenia [prevention & control];
MESH terms:
Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults
1. Adrenergic alpha-1 Receptor Antagonists [*therapeutic use]; 2. Chemotherapy, Adjuvant [methods]; 3. Combined Modality Therapy [methods]; 4. Doxazosin [therapeutic use]; 5. Indoles [therapeutic use]; 6. Kidney Calculi [*therapy]; 7. *Lithotripsy; 8. Prazosin [analogs & derivatives, therapeutic use]; 9. Quinazolines [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Tamsulosin [therapeutic use]; 12. Ureteral Calculi [*therapy];
MESH terms:
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
1. Angiotensin Receptor Antagonists [*therapeutic use]; 2. Angiotensin-Converting Enzyme Inhibitors [*therapeutic use]; 3. Bias; 4. Calcium Channel Blockers [therapeutic use]; 5. Canrenone [therapeutic use]; 6. Disease Progression; 7. Eplerenone [therapeutic use]; 8. Hyperkalemia [chemically induced, prevention & control]; 9. Kidney Failure, Chronic [*drug therapy]; 10. Mineralocorticoid Receptor Antagonists [adverse effects, *therapeutic use]; 11. Naphthyridines [therapeutic use]; 12. Proteinuria [*drug therapy]; 13. Randomized Controlled Trials as Topic; 14. Spironolactone [adverse effects, analogs & derivatives, therapeutic use];
MESH terms:
Calcium channel blockers for people with chronic kidney disease requiring dialysis
1. Antihypertensive Agents [*therapeutic use]; 2. Bias; 3. Blood Pressure [drug effects]; 4. Calcium Channel Blockers [adverse effects, *therapeutic use]; 5. Dihydropyridines [adverse effects, *therapeutic use]; 6. Hypertension [*drug therapy]; 7. Hypotension [chemically induced]; 8. Randomized Controlled Trials as Topic; 9. *Renal Dialysis; 10. Renal Insufficiency, Chronic [complications, *therapy];
MESH terms:
Oral protein‐based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis
1. Administration, Oral; 2. Arm [anatomy & histology]; 3. Bias; 4. Biomarkers [blood]; 5. Dietary Proteins [*administration & dosage, adverse effects]; 6. Malnutrition [blood, etiology, *therapy]; 7. Peritoneal Dialysis [statistics & numerical data]; 8. Placebos [administration & dosage]; 9. Prealbumin [metabolism]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. *Renal Dialysis [statistics & numerical data]; 13. Renal Insufficiency, Chronic [blood, complications, *therapy]; 14. Serum Albumin [*metabolism]; 15. Skinfold Thickness;
MESH terms:
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
1. Everolimus [*therapeutic use]; 2. Immunosuppression Therapy; 3. Immunosuppressive Agents [adverse effects, *therapeutic use]; 4. Kidney Failure, Chronic [surgery]; 5. *Kidney Transplantation; 6. Randomized Controlled Trials as Topic; 7. Sirolimus [analogs & derivatives, antagonists & inhibitors, *therapeutic use];
MESH terms:
Interventions for preventing bone disease in kidney transplant recipients
1. Bone Density [drug effects]; 2. Bone Diseases [etiology, prevention & control]; 3. Calcitonin [therapeutic use]; 4. Calcium [therapeutic use]; 5. Diphosphonates [therapeutic use]; 6. Fractures, Bone [etiology, *prevention & control]; 7. Kidney Diseases [complications]; 8. Kidney Transplantation [*adverse effects]; 9. Randomized Controlled Trials as Topic; 10. Vitamin D [therapeutic use];
MESH terms:
Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
1. *Dialysis Solutions [adverse effects]; 2. *Temperature; 3. Hypotension [*etiology, prevention & control]; 4. Randomized Controlled Trials as Topic; 5. Renal Dialysis; 6. Renal Insufficiency, Chronic [therapy];
MESH terms:
Catheter type, placement and insertion techniques for preventing catheter‐related infections in chronic peritoneal dialysis patients
1. *Peritoneal Dialysis [instrumentation]; 2. Catheter‐Related Infections [*prevention & control]; 3. Catheterization [*methods]; 4. Catheters, Indwelling; 5. Peritonitis [*prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Alpha‐blockers as medical expulsive therapy for ureteral stones
1. Adrenergic alpha-Antagonists [adverse effects, *therapeutic use]; 2. Analgesics [therapeutic use]; 3. Diclofenac [therapeutic use]; 4. Hospitalization [statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; 7. Ureteral Calculi [diagnostic imaging, *drug therapy];
MESH terms:
Medical and dietary interventions for preventing recurrent urinary stones in children
1. Administration, Oral; 2. Calcium; 3. Kidney Calculi [chemistry, *prevention & control]; 4. Lithotripsy [methods]; 5. Potassium Citrate [*administration & dosage, adverse effects]; 6. Recurrence; 7. Secondary Prevention [*methods]; 8. Urinary Calculi [prevention & control];
MESH terms:
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
1. Cardiovascular Diseases [epidemiology, prevention & control]; 2. Creatinine [blood]; 3. Disease Progression; 4. Glomerular Filtration Rate; 5. Hyperuricemia [mortality, *therapy]; 6. Incidence; 7. Kidney Failure, Chronic [epidemiology, prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Renal Insufficiency, Chronic [mortality, *prevention & control]; 10. Time Factors; 11. Uric Acid [blood];
MESH terms:
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
1. Antihypertensive Agents [adverse effects, *therapeutic use]; 2. Dopamine [therapeutic use]; 3. Hepatorenal Syndrome [*drug therapy, mortality]; 4. Lypressin [adverse effects, *analogs & derivatives, therapeutic use]; 5. Midodrine [therapeutic use]; 6. Norepinephrine [therapeutic use]; 7. Octreotide [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Terlipressin; 10. Vasoconstrictor Agents [adverse effects, *therapeutic use];
MESH terms:
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
1. Anemia [blood, *drug therapy, etiology]; 2. Cardiovascular Diseases [etiology]; 3. Cause of Death; 4. Darbepoetin alfa [adverse effects, therapeutic use]; 5. Epoetin Alfa [adverse effects, therapeutic use]; 6. Erythrocyte Transfusion [adverse effects, statistics & numerical data]; 7. Erythropoietin [adverse effects, *therapeutic use]; 8. Hypertension [etiology]; 9. Polyethylene Glycols [adverse effects, *therapeutic use]; 10. Publication Bias; 11. Randomized Controlled Trials as Topic; 12. Recombinant Proteins [adverse effects, therapeutic use]; 13. Renal Dialysis; 14. Renal Insufficiency, Chronic [*complications, therapy]; 15. Thrombosis [etiology];
MESH terms:
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
1. *Kidney Transplantation; 2. Acute Disease; 3. Antibodies [*therapeutic use]; 4. Antibodies, Monoclonal [therapeutic use]; 5. Antilymphocyte Serum [therapeutic use]; 6. Drug Resistance; 7. Graft Rejection [*drug therapy]; 8. Immunologic Factors [therapeutic use]; 9. Immunosuppressive Agents [*therapeutic use]; 10. Muromonab‐CD3 [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Rituximab [therapeutic use];
MESH terms:
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
1. Acute Disease; 2. Alemtuzumab; 3. Antibodies, Monoclonal [therapeutic use]; 4. Antibodies, Monoclonal, Humanized [*therapeutic use]; 5. Antilymphocyte Serum [adverse effects, *therapeutic use]; 6. Calcineurin Inhibitors [*therapeutic use]; 7. Cytomegalovirus Infections [etiology]; 8. Graft Rejection [mortality, *prevention & control]; 9. Immunosuppression Therapy [*methods]; 10. Immunosuppressive Agents [adverse effects, *therapeutic use]; 11. *Kidney Transplantation [adverse effects, mortality]; 12. Muromonab-CD3 [therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Receptors, Interleukin-2 [immunology]; 15. Steroids [therapeutic use];
MESH terms:
Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients
1. Anemia [blood, *drug therapy]; 2. Epoetin Alfa [*administration & dosage]; 3. Erythropoietin [*administration & dosage]; 4. Hematinics [*administration & dosage]; 5. Hemoglobin A; 6. Injections, Intravenous; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [administration & dosage]; 9. *Renal Dialysis; 10. Renal Insufficiency, Chronic [*blood];
MESH terms:
Interventions for chronic kidney disease‐associated restless legs syndrome
1. Amines [therapeutic use]; 2. Anticonvulsants [*therapeutic use]; 3. Ascorbic Acid [therapeutic use]; 4. Cyclohexanecarboxylic Acids [therapeutic use]; 5. Dopamine Agonists [*therapeutic use]; 6. Exercise Therapy [*methods]; 7. Gabapentin; 8. gamma-Aminobutyric Acid [therapeutic use]; 9. Indoles [therapeutic use]; 10. Iron-Dextran Complex [therapeutic use]; 11. Levodopa [therapeutic use]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Renal Insufficiency, Chronic [complications, *therapy]; 15. *Renal Replacement Therapy; 16. Resistance Training; 17. Restless Legs Syndrome [complications, *therapy]; 18. Vitamin E [therapeutic use]; 19. Vitamins [therapeutic use];
MESH terms:
Steroid avoidance or withdrawal for kidney transplant recipients
1. *Kidney Transplantation [mortality]; 2. Graft Rejection [immunology, *prevention & control]; 3. Graft Survival [drug effects, immunology]; 4. Immunosuppression Therapy; 5. Immunosuppressive Agents [*administration & dosage, adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Steroids [*administration & dosage, adverse effects]; 8. Withholding Treatment;
MESH terms:
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
1. *Hepacivirus; 2. *Patient Isolation; 3. *Renal Dialysis [instrumentation]; 4. Hepatitis C [epidemiology, *prevention & control, transmission]; 5. Incidence; 6. Randomized Controlled Trials as Topic;
MESH terms:
Normal saline versus lower‐chloride solutions for kidney transplantation
1. *Delayed Graft Function [blood]; 2. *Hyperkalemia [blood, chemically induced]; 3. *Kidney Transplantation; 4. Gluconates [pharmacology]; 5. Hydrogen‐Ion Concentration; 6. Infusions, Intravenous; 7. Isotonic Solutions [pharmacology]; 8. Kidney [*drug effects]; 9. Magnesium Chloride [pharmacology]; 10. Potassium Chloride [pharmacology]; 11. Ringer's Solution; 12. Sodium Acetate [pharmacology]; 13. Sodium Chloride [adverse effects, chemistry, *pharmacology]; 14. Solutions;
MESH terms:
Interventions for lowering plasma homocysteine levels in dialysis patients
1. Cardiovascular Diseases [etiology, *mortality]; 2. Cause of Death; 3. Folic Acid [adverse effects, *therapeutic use]; 4. Homocysteine [blood]; 5. Hyperhomocysteinemia [*drug therapy]; 6. Kidney Failure, Chronic [*blood, therapy]; 7. Myocardial Infarction [epidemiology]; 8. *Renal Dialysis; 9. Stroke [epidemiology]; 10. Venous Thrombosis [epidemiology]; 11. Vitamin B 12 [therapeutic use]; 12. Vitamin B 6 [therapeutic use]; 13. Vitamin B Complex [*therapeutic use];
MESH terms:
Laparoendoscopic single‐site donor nephrectomy (LESS‐DN) versus standard laparoscopic donor nephrectomy
1. *Living Donors; 2. *Transplant Donor Site; 3. Blood Loss, Surgical [statistics & numerical data]; 4. Endoscopy [adverse effects, *methods]; 5. Laparoscopy [adverse effects, *methods]; 6. Length of Stay [statistics & numerical data]; 7. Nephrectomy [adverse effects, *methods]; 8. Operative Time; 9. Pain Measurement; 10. Pain, Postoperative; 11. Randomized Controlled Trials as Topic;
MESH terms:
Antidepressants for treating depression in adults with end‐stage kidney disease treated with dialysis
1. Antidepressive Agents [*therapeutic use]; 2. Citalopram [therapeutic use]; 3. Depression [*therapy]; 4. Fluoxetine [therapeutic use]; 5. Kidney Failure, Chronic [psychology, *therapy]; 6. Psychotherapy; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Renal Dialysis [*psychology]; 10. Sertraline [therapeutic use];
MESH terms:
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease
1. *Catheter Obstruction; 2. *Central Venous Catheters; 3. Anticoagulants [*administration & dosage]; 4. Bacteremia [prevention & control]; 5. Catheter‐Related Infections [prevention & control]; 6. Heparin [administration & dosage]; 7. Kidney Failure, Chronic [*therapy]; 8. Platelet Aggregation Inhibitors [*administration & dosage]; 9. Randomized Controlled Trials as Topic; 10. Renal Dialysis [*instrumentation];
MESH terms:
Pre‐emptive correction for haemodialysis arteriovenous access stenosis
1. *Arteriovenous Shunt, Surgical [adverse effects]; 2. *Renal Dialysis; 3. Constriction, Pathologic [diagnosis, prevention & control]; 4. Kidney Failure, Chronic [*therapy]; 5. Primary Prevention; 6. Randomized Controlled Trials as Topic; 7. Secondary Prevention; 8. Thrombosis [diagnosis];
MESH terms:
Early versus delayed erythropoietin for the anaemia of end‐stage kidney disease
1. Anemia [*drug therapy, etiology]; 2. Erythropoietin [*therapeutic use]; 3. Hematinics [therapeutic use]; 4. Kidney Failure, Chronic [*complications, therapy]; 5. Renal Dialysis;
MESH terms:
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
1. *Kidney Transplantation [mortality]; 2. Azathioprine [*therapeutic use]; 3. Cyclosporine [therapeutic use]; 4. Graft Rejection [mortality, *prevention & control]; 5. Immunosuppression Therapy [*methods]; 6. Immunosuppressive Agents [*therapeutic use]; 7. Mycophenolic Acid [*analogs & derivatives, therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
1. Amphotericin B [adverse effects, *therapeutic use]; 2. Antifungal Agents [adverse effects, *therapeutic use]; 3. Chills [chemically induced]; 4. Creatinine [blood]; 5. Deoxycholic Acid [adverse effects, *therapeutic use]; 6. Drug Combinations; 7. Fever [chemically induced]; 8. Kidney [*drug effects]; 9. Nausea [chemically induced]; 10. Randomized Controlled Trials as Topic; 11. Vomiting [chemically induced];
MESH terms:
Citrate salts for preventing and treating calcium containing kidney stones in adults
1. Calcium Oxalate; 2. Calcium Phosphates; 3. Citrates [adverse effects, *therapeutic use, urine]; 4. Drug Combinations; 5. Kidney Calculi [*chemistry, prevention & control, *therapy]; 6. Magnesium Compounds [therapeutic use]; 7. Potassium Compounds [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Secondary Prevention;
MESH terms:
Dietary interventions for mineral and bone disorder in people with chronic kidney disease
1. *Bread; 2. Acetates [administration & dosage]; 3. Alkaline Phosphatase [blood]; 4. Bone Density; 5. Bone Diseases, Metabolic [blood, etiology, *therapy]; 6. Calcium [blood]; 7. Calcium Compounds [administration & dosage]; 8. Calcium Phosphates [blood]; 9. Calcium, Dietary [*administration & dosage]; 10. Dietary Proteins [administration & dosage]; 11. Fibroblast Growth Factor‐23; 12. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [administration & dosage]; 13. Phosphorus [administration & dosage, *blood]; 14. Randomized Controlled Trials as Topic; 15. Renal Insufficiency, Chronic [*complications];
MESH terms:
Nonsteroidal anti‐inflammatory drugs (NSAIDs) and non‐opioids for acute renal colic
1. Acute Disease; 2. Analgesics, Non‐Narcotic [*therapeutic use]; 3. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 4. Diclofenac [therapeutic use]; 5. Indomethacin [therapeutic use]; 6. Parasympatholytics [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Renal Colic [*drug therapy]; 9. Scopolamine [therapeutic use];
MESH terms:
Haemodiafiltration, haemofiltration and haemodialysis for end‐stage kidney disease
1. Cardiovascular Diseases [mortality]; 2. Cause of Death; 3. Hemodiafiltration [adverse effects, methods]; 4. Hemofiltration [adverse effects, *methods]; 5. Hospitalization; 6. Hypotension [etiology]; 7. Kidney Failure, Chronic [*therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for lowering plasma homocysteine levels in kidney transplant recipients
1. *Kidney Transplantation; 2. Cardiovascular Diseases [*mortality]; 3. Cause of Death; 4. Folic Acid [*administration & dosage]; 5. Homocysteine [*blood]; 6. Randomized Controlled Trials as Topic; 7. Vitamin B Complex [*administration & dosage];
MESH terms:
Bicarbonate‐ versus lactate‐buffered solutions for acute continuous haemodiafiltration or haemofiltration
1. Acute Kidney Injury [blood, mortality, *therapy]; 2. Bicarbonates [adverse effects, blood, *therapeutic use]; 3. Blood Pressure; 4. Buffers; 5. Creatinine [blood]; 6. Dialysis Solutions [adverse effects, *therapeutic use]; 7. Hemodiafiltration [methods]; 8. Hemofiltration [*methods]; 9. Lactates [*administration & dosage, adverse effects]; 10. Lactic Acid [blood]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Loop diuretics for patients receiving blood transfusions
1. *Transfusion Reaction; 2. Body Water; 3. Confidence Intervals; 4. Furosemide [*administration & dosage]; 5. Infant, Premature; 6. Pulmonary Edema [etiology, *prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Sodium Potassium Chloride Symporter Inhibitors [*administration & dosage];
MESH terms:
Belatacept for kidney transplant recipients
1. *Kidney Transplantation [mortality]; 2. Abatacept; 3. Alemtuzumab; 4. Antibodies, Monoclonal [therapeutic use]; 5. Antibodies, Monoclonal, Humanized [therapeutic use]; 6. Antilymphocyte Serum [therapeutic use]; 7. Basiliximab; 8. Calcineurin Inhibitors [*therapeutic use]; 9. Cyclosporine [therapeutic use]; 10. Graft Rejection [mortality, *prevention & control]; 11. Graft Survival; 12. Immunoconjugates [adverse effects, *therapeutic use]; 13. Immunosuppressive Agents [adverse effects, *therapeutic use]; 14. Lymphoproliferative Disorders [etiology]; 15. Mycophenolic Acid [analogs & derivatives, therapeutic use]; 16. Prednisone [therapeutic use]; 17. Randomized Controlled Trials as Topic; 18. Recombinant Fusion Proteins [therapeutic use]; 19. Sirolimus [therapeutic use]; 20. Tacrolimus [therapeutic use];
MESH terms:
Oral adsorbents for preventing or delaying the progression of chronic kidney disease
1. Administration, Oral; 2. Adsorption; 3. Carbon [*administration & dosage, adverse effects]; 4. Disease Progression; 5. Oxides [*administration & dosage, adverse effects]; 6. Phytotherapy [adverse effects, methods]; 7. Randomized Controlled Trials as Topic; 8. Renal Insufficiency, Chronic [*prevention & control];
MESH terms:
Androgens for the anaemia of chronic kidney disease in adults
1. Androgens [*therapeutic use]; 2. Anemia [blood, *drug therapy, etiology]; 3. Cholesterol [blood]; 4. Erythropoietin [therapeutic use]; 5. Hematocrit; 6. Nandrolone [analogs & derivatives, therapeutic use]; 7. Nandrolone Decanoate; 8. Oxymetholone [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Renal Insufficiency, Chronic [*complications]; 11. Triglycerides [blood];
MESH terms:
Dietary interventions for preventing complications in idiopathic hypercalciuria
1. Calcium, Dietary [administration & dosage]; 2. Diet, Protein‐Restricted; 3. Diet, Sodium‐Restricted; 4. Hypercalciuria [complications, *diet therapy]; 5. Hyperoxaluria [prevention & control]; 6. Nephrolithiasis [*diet therapy, prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
1. Cardiovascular Diseases [mortality, *prevention & control]; 2. Cholesterol [blood]; 3. Graft Rejection [prevention & control]; 4. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; 5. Hypolipidemic Agents [therapeutic use]; 6. Kidney Transplantation [*mortality]; 7. Myocardial Infarction [prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Triglycerides [blood];
MESH terms:
Lipid‐lowering agents for nephrotic syndrome
1. Fatty Acids, Monounsaturated [therapeutic use]; 2. Fluvastatin; 3. Gemfibrozil [therapeutic use]; 4. Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]; 5. Hypolipidemic Agents [therapeutic use]; 6. Indoles [therapeutic use]; 7. Lovastatin [therapeutic use]; 8. Nephrotic Syndrome [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Simvastatin [therapeutic use];
MESH terms:
Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsy
1. *Diuresis; 2. Diuretics [administration & dosage]; 3. Drainage [*methods]; 4. Drinking Water [administration & dosage]; 5. Furosemide [administration & dosage]; 6. Head-Down Tilt; 7. Kidney Calculi [*therapy]; 8. Patient Positioning [*methods]; 9. Percussion [*methods]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit
1. Arteries; 2. Intensive Care Units; 3. *Lung Injury; 4. Oxygen [adverse effects]; 5. *Respiratory Distress Syndrome;
MESH terms:
Nicotine receptor partial agonists for smoking cessation
1. *Alkaloids [adverse effects]; 2. Bupropion [adverse effects]; 3. *Electronic Nicotine Delivery Systems; 4. Nicotine [adverse effects]; 5. Nicotinic Agonists [adverse effects]; 6. *Smoking Cessation [methods]; 7. Tobacco Use Cessation Devices; 8. Varenicline [adverse effects];
MESH terms:
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
1. Adrenal Cortex Hormones [therapeutic use]; 2. Adrenergic beta-2 Receptor Agonists [therapeutic use]; 3. Muscarinic Antagonists; 4. *Pneumonia [drug therapy]; 5. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 6. Quality of Life;
MESH terms:
Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease
1. Adrenal Cortex Hormones [therapeutic use]; 2. Bronchodilator Agents [adverse effects]; 3. Disease Progression; 4. *Pneumonia [drug therapy]; 5. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 6. Quality of Life;
MESH terms:
Exercise‐based rehabilitation programmes for pulmonary hypertension
1. Bias; 2. Exercise; 3. Exercise Therapy [adverse effects]; 4. *Hypertension, Pulmonary; 5. Quality of Life;
MESH terms:
Pharmacological treatment for central sleep apnoea in adults
1. Acetazolamide; 2. Apnea; 3. Buspirone; 4. Carbonic Anhydrase Inhibitors; 5. *Disorders of Excessive Somnolence; 6. *Heart Failure; 7. Hypnotics and Sedatives; 8. *Sleep Apnea, Central [drug therapy]; 9. Theophylline; 10. *Triazolam;
MESH terms:
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD)
1. *Breathing Exercises; 2. Dyspnea [rehabilitation]; 3. Muscles; 4. *Physical Therapy Modalities; 5. *Pulmonary Disease, Chronic Obstructive [therapy]; 6. Quality of Life;
MESH terms:
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease
1. Adjuvants, Immunologic [therapeutic use]; 2. Anti-Bacterial Agents [therapeutic use]; 3. *Bronchitis, Chronic [drug therapy]; 4. Disease Progression; 5. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 6. Quality of Life;
MESH terms:
Non‐invasive positive pressure ventilation for central sleep apnoea in adults
1. Continuous Positive Airway Pressure; 2. *Disorders of Excessive Somnolence; 3. *Heart Failure; 4. *Sleep Apnea, Central [therapy]; 5. *Sleep Apnea, Obstructive [therapy];
MESH terms:
Pulmonary rehabilitation versus usual care for adults with asthma
1. *Asthma; 2. Dyspnea [rehabilitation]; 3. Hospitalization; 4. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 5. Quality of Life;
MESH terms:
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
1. Disease Progression; 2. Dyspnea [drug therapy, etiology]; 3. Ipratropium [therapeutic use]; 4. Magnesium [therapeutic use]; 5. *Magnesium Sulfate [adverse effects]; 6. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing weight gain after smoking cessation
1. *Electronic Nicotine Delivery Systems; 2. Nicotine; 3. *Smoking Cessation; 4. Tobacco Use Cessation Devices; 5. Weight Gain;
MESH terms:
Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea
1. Continuous Positive Airway Pressure; 2. *Erectile Dysfunction [therapy]; 3. Incidence; 4. Intubation; 5. Randomized Controlled Trials as Topic; 6. *Sleep Apnea, Obstructive [complications, therapy];
MESH terms:
Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease
1. Exercise [*psychology]; 2. *Exercise Tolerance; 3. Pulmonary Disease, Chronic Obstructive [*rehabilitation]; 4. Quality of Life [*psychology]; 5. Standard of Care; 6. *Telerehabilitation;
MESH terms:
Chronic non‐invasive ventilation for chronic obstructive pulmonary disease
1. Disease Progression; 2. Dyspnea; 3. *Noninvasive Ventilation; 4. *Pulmonary Disease, Chronic Obstructive [therapy]; 5. Quality of Life; 6. *Respiratory Insufficiency [etiology, therapy];
MESH terms:
Glucocorticoid with cyclophosphamide for oral paraquat poisoning
1. Bias; 2. Cause of Death; 3. Cyclophosphamide [*therapeutic use]; 4. Drug Therapy, Combination [methods]; 5. Glucocorticoids [*therapeutic use]; 6. Herbicides [*poisoning]; 7. Immunosuppressive Agents [*therapeutic use]; 8. Paraquat [*poisoning]; 9. Poisoning [drug therapy, mortality]; 10. Pulmonary Fibrosis [chemically induced, *drug therapy, immunology, mortality]; 11. Randomized Controlled Trials as Topic; 12. Time Factors;
MESH terms:
Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma
1. Adrenal Cortex Hormones [*administration & dosage]; 2. Adrenergic beta-2 Receptor Agonists [*administration & dosage]; 3. Anti-Asthmatic Agents [*administration & dosage]; 4. Asthma [*drug therapy]; 5. Beclomethasone [administration & dosage]; 6. Budesonide [*administration & dosage]; 7. Disease Progression; 8. Drug Combinations; 9. Formoterol Fumarate [*administration & dosage]; 10. Hospitalization [statistics & numerical data]; 11. Nebulizers and Vaporizers; 12. Prednisolone [administration & dosage]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Terbutaline [administration & dosage];
MESH terms:
Interventions for tobacco cessation delivered by dental professionals
1. Bias; 2. *Counseling; 3. *Dentists; 4. Oral Health; 5. Randomized Controlled Trials as Topic; 6. Schools; 7. Smoking Cessation [methods, psychology]; 8. Tobacco Use Cessation [*methods, psychology]; 9. Tobacco, Smokeless [adverse effects]; 10. Universities;
MESH terms:
Telerehabilitation for chronic respiratory disease
1. Bias; 2. Chronic Disease; 3. Controlled Clinical Trials as Topic [statistics & numerical data]; 4. Dyspnea [rehabilitation]; 5. Exercise Tolerance [physiology]; 6. Internet [statistics & numerical data]; 7. Non-Randomized Controlled Trials as Topic [statistics & numerical data]; 8. Patient Compliance [statistics & numerical data]; 9. Pulmonary Disease, Chronic Obstructive [*rehabilitation]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic [statistics & numerical data]; 12. Respiration Disorders [*rehabilitation]; 13. Telephone [statistics & numerical data]; 14. Telerehabilitation [*methods, statistics & numerical data]; 15. Videoconferencing [statistics & numerical data]; 16. Walk Test [statistics & numerical data];
MESH terms:
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. Antibiotic Prophylaxis [adverse effects, *methods]; 3. Bacterial Load [*drug effects]; 4. Bayes Theorem; 5. Bias; 6. *Disease Progression; 7. Forced Expiratory Volume; 8. Macrolides [adverse effects, therapeutic use]; 9. *Network Meta-Analysis; 10. Pulmonary Disease, Chronic Obstructive [complications, *drug therapy, microbiology]; 11. Quality of Life; 12. Quinolones [adverse effects, therapeutic use]; 13. Randomized Controlled Trials as Topic [statistics & numerical data]; 14. Tetracyclines [adverse effects, therapeutic use]; 15. Treatment Outcome;
MESH terms:
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
1. Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; 2. Bias; 3. Disease Progression; 4. Eosinophils; 5. Hospitalization [statistics & numerical data]; 6. Interleukin-5 [*antagonists & inhibitors]; 7. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Receptors, Interleukin-5 [*antagonists & inhibitors];
MESH terms:
Proton pump inhibitors for chronic obstructive pulmonary disease
1. *Disease Progression; 2. Lansoprazole [*therapeutic use]; 3. Proton Pump Inhibitors [*therapeutic use]; 4. Pulmonary Disease, Chronic Obstructive [*drug therapy, prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Tract Infections [epidemiology];